secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001558370-22-016731
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics reports Q3 net income $17.6M; Pfizer exercises TRACER capsid option
--------------------------------------------------------------------------------

- Collaboration revenue $41.1M (vs $1.5M YoY) driven by $40M Pfizer option exercise recognition.
- Net income $17.6M vs loss of $25.1M; cash $131.6M plus $10M Pfizer payment received in October.
- Pfizer exercised option to license novel capsid; $10M payment, up to $290M in milestones plus tiered royalties.
- Pipeline: lead development candidates for GBA1, SOD1, anti-tau programs expected Q4 2022 to H1 2023.
- Novartis option decision on TRACER capsids for up to 5 targets expected by March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837022016731/0001558370-22-016731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837022016731/vygr-20221108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-016731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer